BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22332769)

  • 21. [Myocardial metastasis from renal cell carcinoma treated with sorafenib].
    Tokuyama Y; Iwamura M; Fujita T; Sugita A; Maeyama R; Bessho H; Ishikawa W; Tabata K; Yoshida K; Baba S
    Hinyokika Kiyo; 2011 Oct; 57(10):555-8. PubMed ID: 22089153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract]   [Full Text] [Related]  

  • 23. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
    Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
    Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting renal cell carcinoma.
    Motzer RJ; Molina AM
    J Clin Oncol; 2009 Jul; 27(20):3274-6. PubMed ID: 19451422
    [No Abstract]   [Full Text] [Related]  

  • 25. Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?
    Procopio G; Verzoni E; Guadalupi V; Iacovelli R; Bajetta E
    Tumori; 2010; 96(5):794-5. PubMed ID: 21302633
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
    Ruppin S; Protzel C; Klebingat KJ; Hakenberg OW
    Eur Urol; 2009 Apr; 55(4):986-8; quiz 988. PubMed ID: 19004541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized discontinuation trial of sorafenib (BAY 43-9006).
    Jain L; Venitz J; Figg WD
    Cancer Biol Ther; 2006 Oct; 5(10):1270-2. PubMed ID: 16969070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.
    Castagneto B; Stevani I; Giorcelli L; Montefiore F; Bigatti GL; Pisacco P; Cosimi MF
    Med Oncol; 2011 Dec; 28(4):1384-8. PubMed ID: 20552299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
    Mego M; Reckova M; Obertova J; Sycova-Mila Z; Brozmanova K; Mardiak J
    Ann Oncol; 2007 Nov; 18(11):1906-7. PubMed ID: 17993633
    [No Abstract]   [Full Text] [Related]  

  • 30. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
    Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
    Bellmunt J; Maroto-Rey P; Trigo JM; Carles J; Guillem V; López-Martín JA; Antón-Torres A; Urruticoechea L
    Clin Transl Oncol; 2010 Jul; 12(7):503-8. PubMed ID: 20615828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapeutic options for renal cell carcinoma.
    Stadler W
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
    [No Abstract]   [Full Text] [Related]  

  • 33. Biomarkers in renal cell carcinoma: what next?
    Bukowski RM
    Curr Oncol Rep; 2011 Apr; 13(2):87-9. PubMed ID: 21271363
    [No Abstract]   [Full Text] [Related]  

  • 34. [Sorafenib(Nexavar)].
    Miyanaga N; Akaza H
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
    Massard C; Zonierek J; Gross-Goupil M; Fizazi K; Szczylik C; Escudier B
    Ann Oncol; 2010 May; 21(5):1027-31. PubMed ID: 19850637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
    Bellmunt J; Fishman M; Eisen T; Quinn D
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
    Hou MM; Hsieh JJ; Chang NJ; Huang HY; Wang HM; Chuang CK; Hsu T; Chang JW
    Clin Drug Investig; 2010; 30(11):799-804. PubMed ID: 20635828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
    Vira MA; Novakovic KR; Pinto PA; Linehan WM
    BJU Int; 2007 May; 99(5 Pt B):1223-9. PubMed ID: 17441915
    [No Abstract]   [Full Text] [Related]  

  • 39. Successful treatment of a brain-metastasized renal cell carcinoma.
    Walid MS; Johnston KW
    Ger Med Sci; 2009 Oct; 7():Doc28. PubMed ID: 19911072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Richards TM; Plowman PN; Reznek R; Ball SA
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.